EPHA5 and cancer: Similarly, in the Memorial Sloan Kettering Cancer Center (MSKCC) immunotherapy cohort (Supplementary Table 1), EPHA5-Mut LUAD cancers also exhibited a significantly higher TMB than EPHA5-WT LUAD cancers, indicating a convincing association between EPHA5 mutations and TMB (Figure 4B).